Amicus Therapeutics Prices Underwritten Offering of Common Stock
May 30 2019 - 9:00PM
Amicus Therapeutics (Nasdaq: FOLD) today announced the pricing of
an underwritten offering of 16,279,070 shares of its common stock
at $10.75 per share. The gross proceeds from the offering to Amicus
are expected to be $175 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable
by Amicus. In addition, Amicus has granted the underwriters a
30-day option to purchase up to an additional 2,441,860 shares of
its common stock. The offering is expected to close on June 4, 2019
subject to customary closing conditions.
J.P. Morgan Securities LLC, Goldman Sachs &
Co. LLC, and SVB Leerink LLC are acting as joint book-running
managers for the offering.
The Company expects to use the net proceeds of
the offering for investment in the development of the expanded gene
therapy pipeline, manufacturing capabilities for Pompe biologic
AT-GAA and gene therapy product candidates, including contract
manufacturing partnerships, completion of the design and build of
the Amicus Process Science and Gene Therapy Manufacturing facility
and for other general corporate and product development
purposes.
The securities described above are being offered
by Amicus pursuant to a registration statement previously filed
with the U.S. Securities and Exchange Commission (the “SEC”) on
April 24, 2019, which became automatically effective upon the
filing thereof. A preliminary prospectus supplement relating
to the offering was filed with the SEC on May 30, 2019.
Copies of the preliminary prospectus supplement and accompanying
base prospectus relating to the offering may be obtained by
contacting J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717
(telephone number: 866-803-9204), Goldman Sachs & Co. LLC, by
mail, Attn: Prospectus Department, 200 West Street, New York, NY
10282, by facsimile: 212-902-9316, by email:
prospectus-ny@ny.email.gs.com; or by telephone: 866-471-2526, or
SVB Leerink LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA 02110, or by
telephone at (800) 808-7525, ext. 6132, or by email
at syndicate@svbleerink.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities
described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
metabolic diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for
rare metabolic diseases.
Forward-Looking
StatementsStatements regarding the proposed public
offering constitute forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. There can be no assurance
that Amicus will be able to complete the proposed offering of
common stock on acceptable terms, or at all. Actual results
or events may differ materially from those indicated by
forward-looking statements as a result of various risks,
uncertainties and important factors, including those set forth in
the “Risk Factors” section in the preliminary prospectus supplement
relating to the offering. In addition, all forward-looking
statements are subject to other risks detailed in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2018,
and Quarterly Report on Form 10-Q for the quarter ended March 31,
2019. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Amicus undertakes no
obligation to revise or update this news release to reflect events
or circumstances after the date hereof.
CONTACTS:
Investors/Media:Amicus TherapeuticsSara
Pellegrino, IRCVice President, Investor Relations & Corporate
Communicationsspellegrino@amicusrx.com (609) 662-5044
Media:Amicus TherapeuticsMarco WinklerDirector,
Corporate Communicationsmwinkler@amicusrx.com(609) 662-2798
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Sep 2024 to Oct 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Oct 2023 to Oct 2024